文献速递胸部肿瘤

塞来昔布联合标准化疗治疗环氧合酶-2过表达晚期非小细胞肺癌的III期随机安慰剂对照双盲试验:CALGB 30801(Alliance)

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
PubMed 文献 · J Clin Oncol · 2017-05-10

在COX-2免疫组化表达≥2的晚期非小细胞肺癌患者中,按组织学给予卡铂联合培美曲塞或吉西他滨化疗,随机加用塞来昔布400mg每日两次或安慰剂。计划322例COX-2指数≥2患者中随机312例后因无效提前终止,COX-2≥4者风险比1.046,无显著差异。基线尿前列腺素E2代谢物升高为不良预后因素,高于第三四分位值可能是预测因素。

要点

  • COX-2免疫组化未能筛选出可从选择性COX-2抑制中获益的患者。
  • COX-2指数≥4者塞来昔布组与安慰剂组风险比1.046,无显著差异。
  • 基线尿前列腺素E2代谢物升高为不良预后因素,高于第三四分位值可能是预测因素。

核心结论

  • COX-2免疫组化未能筛选出可从选择性COX-2抑制中获益的晚期非小细胞肺癌患者。

研究设计与样本

  • III期随机、安慰剂对照、双盲试验,纳入COX-2免疫组化表达≥2、体能状态0-2、器官功能正常的晚期非小细胞肺癌患者(IIIB期伴胸腔积液或IV期,根据美国癌症联合委员会第六版标准)。
  • 化疗按组织学确定:非鳞癌用卡铂联合培美曲塞,鳞癌用卡铂联合吉西他滨;随机分配至塞来昔布400mg每日两次(A组)或安慰剂(B组)。
  • 主要目标为在COX-2指数≥4患者中证明无进展生存改善,风险比0.645,约85%把握度,双侧显著性水平0.05;计划随机322例COX-2指数≥2患者,实际随机312例后因无效提前终止。

主要发现

  • COX-2指数≥2患者中随机312例后研究因无效提前终止,两组间无显著差异(COX-2≥4者风险比1.046)。
  • 按组织学、化疗方案和COX-2表达递增进行的亚组分析均未显示COX-2抑制有任何优势。
  • 基线尿前列腺素E2代谢物升高(提示COX-2通路激活)为不良预后因素;高于第三四分位值可能是预测因素。

关键数值与推荐

  • COX-2免疫组化表达≥2为入组条件;主要分析人群为COX-2指数≥4。
  • 塞来昔布剂量为400mg每日两次(A组),安慰剂为B组。
  • 非鳞癌化疗为卡铂联合培美曲塞,鳞癌为卡铂联合吉西他滨。

临床怎么用

  • 原文结论认为COX-2免疫组化未能筛选出可从选择性COX-2抑制中获益的患者,尿前列腺素E2代谢物可能识别可从COX-2抑制中获益的患者。

局限性

  • 研究在计划322例COX-2指数≥2患者中随机312例后因无效提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with worse outcome in non-small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B (CALGB) 30203, we found that the selective COX-2 inhibitor celecoxib in addition to chemotherapy in advanced NSCLC improved progression-free and overall survival in patients with moderate to high COX-2 expression by immunohistochemistry (IHC). CALGB 30801 (Alliance) was designed to prospectively confirm that finding. Patients and Methods Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint Committee on Cancer [sixth edition] criteria) were preregistered, and biopsy specimens were analyzed for COX-2 by IHC. Patients with COX-2 expression ≥ 2, performance status of 0 to 2, and normal organ function were eligible. Chemotherapy was determined by histology: carboplatin plus pemetrexed for nonsquamous NSCLC and carboplatin plus gemcitabine for squamous histology. Patients were randomly assigned to celecoxib (400 mg twice per day; arm A) or placebo (arm B). The primary objective was to demonstrate improvement in progression-free survival in patients with COX-2 index ≥ 4 with hazard ratio of 0.645 with approximately 85% power at two-sided significance level of .05. Results The study was halted for futility after 312 of the planned 322 patients with COX-2 index ≥ 2 were randomly assigned. There were no significant differences between the groups (hazard ratio, 1.046 for COX-2 ≥ 4). Subset analyses evaluating histology, chemotherapy regimen, and incremental COX-2 expression did not demonstrate any advantage for COX-2 inhibition. Elevation of baseline urinary metabolite of prostaglandin E2, indicating activation of the COX-2 pathway, was a negative prognostic factor. Values above the third quartile may have been a predictive factor. Conclusion COX-2 expression by IHC failed to select patients who could benefit from selective COX-2 inhibition. Urinary metabolite of prostaglandin E2 may be able to identify patients who could benefit from COX-2 inhibition.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Edelman MJ, Wang X, Hodgson L, et al. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017. PMID: 28489511. doi:10.1200/JCO.2016.71.3743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。